Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1

This phase 2 study investigated long-term safety and efficacy of rilpivirine (RPV) plus two investigator-selected nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in HIV-1-infected antiviral therapy-naive adolescents. Participants (≥12 to <18 years of age) were treated with RPV at 25 mg onc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombaard, Johan, Ssali, Francis, Thanyawee, Puthanakit, Fourie, Jan, Vanveggel, Simon, Linthicum, Cornelia, Van Eygen, Veerle, Van Solingen-Ristea, Rodica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846324/
https://www.ncbi.nlm.nih.gov/pubmed/34871089
http://dx.doi.org/10.1128/aac.00916-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846324/
https://www.ncbi.nlm.nih.gov/pubmed/34871089
http://dx.doi.org/10.1128/aac.00916-21

Ejemplares similares